Patents Examined by Mary M. Schmidt
  • Prevention and treatment for retinal ischemia and edema
    Patent number: 6670321
    Abstract: The claimed invention relates to methods of treating retinopathy, retinal ischemia and/or retinal edema comprising administering an integrin antagonist, a leukocyte adhesion inducing cytokine antagonist, a selectin antagonist or adhesion molecule antagonist.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: December 30, 2003
    Assignee: The Children's Medical Center Corporation
    Inventor: Anthony P. Adamis
  • Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
    Patent number: 6593305
    Abstract: Compounds and methods for modulating cell proliferation, preferably inhibiting the proliferation of tumor cells are described. Compounds that may be used to modulate cell proliferation include antisense oligonucleotides complementary to regions of the mammalian ribonucleotide reductase genes.
    Type: Grant
    Filed: February 11, 1999
    Date of Patent: July 15, 2003
    Assignee: GeneSense Technologies Inc.
    Inventor: Jim A. Wright
  • Combinatorial antisense library
    Patent number: 6518017
    Abstract: Combinatorial libraries comprise first oligonucleotide analogs and second oligonucleotide analogs which are coupled together to form antisense molecules capable of binding target polynucleotides and activating an RNase, and ribozymes capable of cleaving polynucleotides.
    Type: Grant
    Filed: August 18, 1998
    Date of Patent: February 11, 2003
    Assignee: Oasis Biosciences Incorporated
    Inventors: Timothy A. Riley, Bob D. Brown, Lyle J. Arnold
  • Antisense modulation of helicase-moi expression
    Patent number: 6444466
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of helicase-moi. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding helicase-moi. Methods of using these compounds for modulation of helicase-moi expression and for treatment of diseases associated with expression of helicase-moi are provided.
    Type: Grant
    Filed: May 10, 2001
    Date of Patent: September 3, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Donna T. Ward, Andrew T. Watt
  • DNA encoding DP. 75 and a process for its use
    Patent number: 6300484
    Abstract: The present invention is a novel nucleic acid sequence which hybridizes to SEQ ID NO:6 or fragments thereof under stringent conditions, or fragments thereof. The invention also includes diagnostic assays, expression vectors, control sequences, antisense molecule, ribozymes, and host cells to express the polypeptide encoded by the nucleic acid sequence. The present invention also includes claims to the polypeptide sequence coded by the nucleic acid sequences.
    Type: Grant
    Filed: September 30, 1998
    Date of Patent: October 9, 2001
    Assignee: Chiron Corporation
    Inventor: David Duhl
  • Prostate cancer-specific marker
    Patent number: 6218523
    Abstract: This invention provides cDNA encoding a prostate-cancer specific marker, Repro-PC-1.0, Repro-PC-1.0 polypeptides and methods for use in diagnosis and therapy.
    Type: Grant
    Filed: March 6, 1998
    Date of Patent: April 17, 2001
    Assignee: Diagnostic Products Corporation
    Inventors: Cynthia K. French, Patrick A. Schneider, Karen K. Yamamoto